Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes

Nauck, Michael, Frid, Anders, Hermansen, Kjeld, Shah, Nalini S., Tankova, Tsvetalina, Mitha, Ismail H., Zdravkovic, Milan, Düring, Maria +2 more·2009·Diabetes Care

DOI 10.2337/dc08-1355

Cited by (999)

Items 301–400 of 999

Incretin agents in type 2 diabetes.
Stuart A. Ross, Jean-Marie Ékoé · 2010 · PubMed Central
The role of GLP‐1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide
Anthony H Barnett · 2011 · Diabetes Obesity and Metabolism
Absence of QTc Prolongation in a Thorough QT Study With Subcutaneous Liraglutide, a Once‐Daily Human GLP‐1 Analog for Treatment of Type 2 Diabetes
Chatterjee, Dhruba J., Khutoryansky, Naum, Zdravkovic, Milan, Sprenger, Craig R., Litwin, Jeffrey S. · 2009 · The Journal of Clinical Pharmacology
Patient‐reported outcomes in trials of incretin‐based therapies in patients with type 2 diabetes mellitus
Melanie Jane Davies, Jane Speight · 2012 · Diabetes Obesity and Metabolism
Liraglutide Treatment Reduces Endothelial Endoplasmic Reticulum Stress and Insulin Resistance in Patients With Diabetes Mellitus
Rosa Bretón‐Romero, Robert M. Weisbrod, Bihua Feng, MONIKA M. HOLBROOK, Darae Ko, Mary Margaret Stathos, Ji‐Yao Zhang, Jessica L. Fetterman, Naomi M. Hamburg · 2018 · Journal of the American Heart Association
Efficacy and Safety of Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus
Matthew Philip Gilbert, Richard E. Pratley · 2009 · The American Journal of Medicine
Novel approaches to restore beta cell function in prediabetes and type 2 diabetes
Vishal A. Salunkhe, Rajakrishnan Veluthakal, Steven E. Kahn, Debbie C. Thurmond · 2018 · Diabetologia
Five-Year Efficacy and Safety Data of Exenatide Once Weekly
Carol Wysham, Leigh MacConell, David G. Maggs, Ming Zhou, Peter S. Griffin, MICHAEL E. TRAUTMANN · 2015 · Mayo Clinic Proceedings
Early therapy for type 2 diabetes in China
Wenying Yang, Jianping Weng · 2014 · The Lancet Diabetes & Endocrinology
Exenatide Exhibits Dose-Dependent Effects on Glycemic Control over 12 Weeks in Japanese Patients with Suboptimally Controlled Type 2 Diabetes
Takashi Kadowaki, Mitsuyoshi Namba, Ayuko Yamamura, Hideaki Sowa, Anne M. Wolka, Robert G. Brodows · 2009 · Endocrine Journal
Incretin-Based Therapies
Joshua J. Neumiller · 2014 · Medical Clinics of North America
Liraglutide (victoza): the first once-daily incretin mimetic injection for type-2 diabetes.
Sylvia Jackson, Tonya S. Martin, Jocelyn D. Jones, David Seal, Frank S. Emanuel · 2010 · PubMed Central
Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
Kang, Yu Mi, Jung, Chang Hee · 2016 · Endocrinology and Metabolism
Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes
Bo Åhrén · 2014 · World Journal of Diabetes
Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial
Matthew James Armstrong, Darren Barton, Piers Gaunt, Diana Hull, Kathy Guo, Deborah D. Stocken, Stephen C. L. Gough, Jeremy Tomlinson, Rachel Mary Brown, Stefan G. Hübscher et al. · 2013 · BMJ Open
Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
Filip Krag Knop, Katrine Bagge Hansen, Filip Krag Knop · 2010 · Diabetes Metabolic Syndrome and Obesity
Lifestyle Changes: Effect of Diet, Exercise, Functional Food, and Obesity Treatment on Lipids and Lipoproteins
Byambaa Enkhmaa, Prasanth N. Surampudi, Erdembileg Anuurad, Lars Berglund · 2015 · Europe PMC (PubMed Central)
Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials
Xu Zhao, Kun Huang, Meijie Zheng, Junting Duan · 2019 · BMC Endocrine Disorders
Efficacy of Anti Hyperglycemic Therapies and the Influence of Baseline Hemoglobin A1C: A Meta-Analysis of the Liraglutide Development Program
Robert R. Henry, John B. Buse, Giorgio Sesti, Melanie Jane Davies, Klaus H. Jensen, Jason Brett, Richard E. Pratley · 2011 · Endocrine Practice
Incretin‐Based Therapies for Type 2 Diabetes Mellitus: Current Status and Future Prospects
Scott R. Drab · 2010 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
Clinical use of liraglutide in type 2 diabetes and its effects on cardiovascular risk factors
Varanasi, Ajay, Patel, Pavan, Makdissi, Antoine, Dhindsa, Sandeep, Chaudhuri, Ajay, Dandona, Paresh · 2012 · Endocrine Practice
Liraglutide in the management of type 2 diabetes
Estela Wajcberg, Amatur Amarah · 2010 · Drug Design Development and Therapy
Efficacy and safety of liraglutide compared to sulphonylurea during R amadan in patients with type 2 diabetes ( LIRA‐R amadan): a randomized trial
Sami T. Azar, Akram Salim Echtay, Wan Mohamad Wan Bebakar, SonaVals araj, ABDELKRIM BERRAH, M. A. K. Omar, Abhay Mutha, Karen Tornøe, Margit S. Kaltoft, Naim Shehadeh · 2016 · Diabetes Obesity and Metabolism
Liraglutide: clinical pharmacology and considerations for therapy
Sisson, Evan M. · 2011 · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Efficacy and Safety of Taspoglutide Versus Sitagliptin for Type 2 Diabetes Mellitus (T-Emerge 4 Trial)
Richard M. Bergenstal, Adriana Costa e Forti, Jean‐Louis Chiasson, Michael Woloschak, Mark N. Boldrin, R. Balena · 2012 · Diabetes Therapy
Diabetes mellitus and gastric emptying: questions and issues in clinical practice
Melvin Samsom, Adil E. Bharucha, John E. Gerich, Kathrin Herrmann, Jörg Limmer, Rainer Linke, David G. Maggs, Jörg R. J. Schirra, Adrian V Vella, Hans‐Jürgen Wörle et al. · 2009 · Diabetes/Metabolism Research and Reviews
Clinical Pharmacology of Incretin Therapies for Type 2 Diabetes Mellitus: Implications for Treatment
Neumiller, Joshua J. · 2011 · Clinical Therapeutics
Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review
Xie, Zeyu, Hu, Jia, Gu, Hangye, Li, Mengting, Chen, Jisheng · 2023 · Frontiers in Endocrinology
Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials
NREU, Besmir, DICEMBRINI, Ilaria, TINTI, Federico, MANNUCCI, Edoardo, MONAMI, Matteo · 2023 · Minerva Endocrinology
Postpartum treatment with liraglutide in combination with metformin versus metformin monotherapy to improve metabolic status and reduce body weight in overweight/obese women with recent gestational diabetes: A double-blind, randomized, placebo-controlled study
Karen E Elkind-Hirsch, Donna Shaler, Renee Harris · 2020 · Journal of Diabetes and its Complications
Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes
Kohei Kaku, Mads Frederik Rasmussen, Tomoyuki Nishida, Yutaka Seino · 2011 · Journal of Diabetes Investigation
One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target
Julio Rosenstock, Helena W. Rodbard, Stephen Charles Bain, David A. D’Alessio, Jochen Seufert, Anne Bloch Thomsen, Claus Bo Svendsen, J. Hans DeVries · 2013 · Journal of Diabetes and its Complications
Contributions of authors
Stephan Albrecht Ender, Andreas Machner, Géza Pap, Johannes Hubbe, Henning Graßhoff, Neumann Hw · 2007 · Acta Orthopaedica
GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials
Katherine Esposito, Carmela Mosca, Clementina Brancario, Paolo Chiodini, Antonio Ceriello, Dario Giugliano · 2011 · Current Medical Research and Opinion
Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance
Sri Harsha Tella, Marc Rendell · 2015 · Therapeutic Advances in Endocrinology and Metabolism
Hypoglycemic effect of Hypericum attenuatum Choisy extracts on type 2 diabetes by regulating glucolipid metabolism and modulating gut microbiota
Du‐Xin Jin, Jun‐Fang He, Xuegang Luo, Tongcun Zhang · 2018 · Journal of Functional Foods
The cardiovascular safety of incretin-based therapies: a review of the evidence
John R. Petrie · 2013 · Cardiovascular Diabetology
Extra‐pancreatic effects of incretin‐based therapies: potential benefit for cardiovascular‐risk management in type 2 diabetes
Renate E. van Genugten, Diane L. Möller-Goede, Daniël H. van Raalte, Michaëla Diamant · 2012 · Diabetes Obesity and Metabolism
Once-Weekly GLP-1 Agonists: How Do They Differ from Exenatide and Liraglutide?
Mikkel Christensen, Filip Krag Knop · 2010 · Current Diabetes Reports
Combining Incretin-Based Therapies With Insulin
Jiten P Vora · 2013 · Diabetes Care
The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials
Meixin Yu, Ruxin Wang, Ling Pei, Xiaofang Zhang, Jinjing Wei, Yun Wen, Han Liu, Haowen Ye, Jinghao Wang, Lihong Wang · 2023 · Diabetology & Metabolic Syndrome
Liraglutide: A Review of Its Use in Adult Patients with Type 2 Diabetes Mellitus
Lesley J. Scott · 2014 · Drugs
Incretin Therapies in the Management of Elderly Patients with Type 2 Diabetes Mellitus
Isabelle Bourdel‐Marchasson, Anja Schweizer, Sylvie Dejager · 2011 · Hospital Practice
Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus
Yutaka Seino, Hiromu Nakajima, Hajime Miyahara, Takashi Kurita, Mark Bush, Fred Yang, Murray W Stewart, For the Albiglutide Study Group · 2009 · Current Medical Research and Opinion
SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives
Carrie McAdam-Marx, Karen N. White, Holly E. Gurgle · 2016 · Vascular Health and Risk Management
Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon‐Like Peptide‐1 Receptor Agonist and Sodium‐Glucose Cotransporter‐2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta‐Analysis
Mengdie Hu, Xiaoling Cai, Wenjia Yang, Simin Zhang, Lin Nie, Linong Ji · 2020 · Journal of the American Heart Association
Long-acting GLP-1RAs
Ji Hyun Chun, Amy Butts · 2020 · JAAPA
Liraglutide is effective in type 2 diabetic patients with sustained endogenous insulin‐secreting capacity
Junji Kozawa, Kana Inoue, Ryuya Iwamoto, 倉敷有紀子, Yukiyoshi Okauchi, Susumu Kashine, Tetsuhiro Kitamura, Norikazu Maeda, Kohei Okita, Hiromi Iwahashi et al. · 2011 · Journal of Diabetes Investigation
Weight Management in Diabetes
Sean Wharton, Arya Mitra Sharma, David C.W. Lau · 2013 · Canadian Journal of Diabetes
Therapies for inter-relating diabetes and obesity – GLP-1 and obesity
Iepsen, Eva W, Torekov, Signe S, Holst, Jens J · 2014 · Expert Opinion on Pharmacotherapy
A Review and Meta-Analysis of the Safety and Efficacy of Using Glucagon-like Peptide-1 Receptor Agonists
Hu, En-Hao, Tsai, Ming-Lung, Lin, Yuan, Chou, Tien-Shin, Chen, Tien-Hsing · 2024 · Medicina
Review of the Therapeutic Uses of Liraglutide
Gina J. Ryan, Karla T. Foster, Lynetta M. Johnson · 2011 · Clinical Therapeutics
Retrospective Real-World Adherence in Patients With Type 2 Diabetes Initiating Once-Daily Liraglutide 1.8 mg or Twice-Daily Exenatide 10 μg
Malmenäs, Maria, Bouchard, Jonathan R., Langer, Jakob · 2013 · Clinical Therapeutics
Effects of Exendin‐4 Alone and With Peptide YY3–36 on Food Intake and Body Weight in Diet‐Induced Obese Rats
Roger D. Reidelberger, Alvin C. Haver, Bettye A. Apenteng, Krista Anders, Sharalyn Steenson · 2010 · Obesity
Practical Use of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Primary Care
Timothy Reid · 2013 · Clinical Diabetes
Twenty-four-week effects of liraglutide on body composition, adherence to appetite, and lipid profile in overweight and obese patients with type 2 diabetes mellitus
Simone Perna, Mariangela Rondanelli, Paolo Astrone, Annalisa Grugnetti, Sebastiano Bruno Solerte, Davide Guido · 2016 · Patient Preference and Adherence
GLP-1 as a target for therapeutic intervention
Surya Panicker Rajeev, John P.H. Wilding · 2016 · Current Opinion in Pharmacology
A 2021 Update on the Use of Liraglutide in the Modern Treatment of ‘Diabesity’: A Narrative Review
Mariana Cornelia Tilinca, Robert Aurelian Tiucă, Alexandru Burlacu, Andreea Varga · 2021 · Medicina
The evolving place of incretin-based therapies in type 2 diabetes
Gallwitz, Baptist · 2010 · Pediatric Nephrology
Obesity and diabetes: the links and common approaches
Haslam, David · 2010 · Primary Care Diabetes
GLP-1R Signaling and Functional Molecules in Incretin Therapy
Wan, Wenwei, Qin, Qikai, Xie, Linshan, Zhang, Hanqing, Wu, Fan, Stevens, Raymond C., Liu, Yan · 2023 · Molecules
Off-label drug use in the treatment of polycystic ovary syndrome
Wendy Vitek, Snigdha Alur-Gupta, Kathleen M. Hoeger · 2015 · Fertility and Sterility
Liraglutide
Caroline M. Perry · 2011 · Drugs
Minireview: Signal Bias, Allosterism, and Polymorphic Variation at the GLP-1R: Implications for Drug Discovery
Cassandra Koole, Emilia E. Savage, Arthur Christopoulos, Laurence J. Miller, Patrick Michael Sexton, Denise L. Wootten · 2013 · Molecular Endocrinology
Insulin- and glucagon-like peptide-1-induced changes in heart rate and vagosympathetic activity: why they matter
Paul Elie Valensi, Sabrina Chiheb, M. Fysekidis · 2013 · Diabetologia
Management of diabolical diabetes mellitus and periodontitis nexus: Are we doing enough?
Abhijit N. Gurav · 2016 · World Journal of Diabetes
Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies
Ling Li, Sheyu Li, Jiali Liu, Ke Deng, Jason Walter Busse, Per Olav Vandvik, Evelyn M. Wong, Zahra N. Sohani, Małgorzata Maria Bała, Lorena P Rios et al. · 2016 · BMC Cardiovascular Disorders
Insights from the Liraglutide Clinical Development Program—the Liraglutide Effect and Action in Diabetes (LEAD) Studies
Janet B. McGill · 2009 · Postgraduate Medicine
Treatment With Liraglutide-a Once-Daily GLP-1 Analog-Does Not Reduce the Bioavailability of Ethinyl Estradiol/Levonorgestrel Taken as an Oral Combination Contraceptive Drug
Jacobsen, Lisbeth V., Vouis, Jan, Hindsberger, Charlotte, Zdravkovic, Milan · 2011 · The Journal of Clinical Pharmacology
Comparison of Sodium–Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide Receptor Agonists for Atrial Fibrillation in Type 2 Diabetes Mellitus: Systematic Review With Network Meta-analysis of Randomized Controlled Trials
Li, Wenjie, Chen, Xingqing, Xie, Xiangqi, Xu, Min, Xu, Lingling, Liu, Peiying, Luo, Bihui · 2022 · Journal of Cardiovascular Pharmacology
Extraglycemic effects of glp-1-based therapeutics: Addressing metabolic and cardiovascular risks associated with type 2 diabetes
Susan Herzlinger, Edward S. Horton · 2013 · Diabetes Research and Clinical Practice
Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study
Kana Inoue, Norikazu Maeda, Yuya Fujishima, Shiro Fukuda, Hirofumi Nagao, Masaya Yamaoka, Ayumu Hirata, Hitoshi Nishizawa, Tohru Funahashi, Iichiro Shimomura · 2014 · Diabetology & Metabolic Syndrome
Glucagon-like peptide-1 prevents methylglyoxal-induced apoptosis of beta cells through improving mitochondrial function and suppressing prolonged AMPK activation
Tien‐Jyun Chang, Hsing-Chi Tseng, Meng-Wei Liu, Yi‐Cheng Chang, Meng-Lun Hsieh, Lee‐Ming Chuang · 2016 · Scientific Reports
Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis
Greer E. Waldrop, Jixin Zhong, Matthew C. Peters, Aditya Goud, Yin‐Hsiu Chen, Stephen N. Davis, Bhramar Mukherjee, Sanjay Rajagopalan · 2016 · Journal of Diabetes and its Complications
Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus
Kasper S Madsen, Pernille Kähler, Lise Katrine Aronsen Kähler, Sten Madsbad, Filip Gnesin, Maria‐Inti Metzendorf, Bernd Richter, Bianca Hemmingsen · 2019 · Cochrane Database of Systematic Reviews
Efficacy and Safety of Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus
Matthew Philip Gilbert, Richard E. Pratley · 2009 · European Journal of Internal Medicine
The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes
David L Russell-Jones · 2010 · International Journal of Clinical Practice
Effectiveness and Persistence with Liraglutide Among Patients with Type 2 Diabetes in Routine Clinical Practice—EVIDENCE: A Prospective, 2-Year Follow-Up, Observational, Post-Marketing Study
Jean–François Gautier, Luc Martinez, Alfred Penfornis, É. Eschwège, Guillaume Charpentier, Benoît Huret, Suliya Madani, Pierre Gourdy · 2015 · Advances in Therapy
Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes: A network meta-analysis
Lin Xia, Tiantian Shen, Wenliang Dong, Su Feng, Jiaxue Wang, Qian Wang, Suping Niu, Yi Fang · 2021 · Diabetes Research and Clinical Practice
Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes
Susan A. Cornell · 2012 · Journal of Clinical Pharmacy and Therapeutics
Co‐administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction
Linda Morrow, Marcus Hompesch, H. Guthrie, D. Chang, Dhruba J. Chatterjee · 2010 · Diabetes Obesity and Metabolism
The Pharmacologic Basis for Clinical Differences among GLP-1 Receptor Agonists and DPP-4 Inhibitors
Javier Morales · 2011 · Postgraduate Medicine
Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review
Østergaard, L., Frandsen, Christian S., Madsbad, S. · 2016 · Expert Review of Clinical Pharmacology
Clinical Approaches to Preserve β-Cell Function in Diabetes
BERNARDO LEO WAJCHENBERG · 2010 · Advances in experimental medicine and biology
Addition of incretin therapy to metformin in type 2 diabetes
André Jacques Scheen, Régis Pierre Radermecker · 2010 · The Lancet
Liraglutide: from clinical trials to clinical practice
S. Gough · 2012 · Diabetes, obesity and metabolism
Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm
John P.H. Wilding, Surya Panicker Rajeev, Ralph Anthony DeFronzo · 2016 · Diabetes Care
Synergistic effects of metformin with liraglutide against endothelial dysfunction through GLP-1 receptor and PKA signalling pathway
Jing Ke, Ye Liu, Jin Yang, Ran Lu, Qing Tian, Wenfang Hou, Guang Wang, Rui Wei, Tianpei Hong · 2017 · Scientific Reports
Real‐world GLP‐1 RA therapy in type 2 diabetes: A long‐term effectiveness observational study
Santiago Tofé, Iñaki Argüelles, Elena Mena, Guillermo Serra, Mercedes Codina, Juan Ramón Urgelés, Honorato García, Vicente Pereg · 2018 · Endocrinology Diabetes & Metabolism
Adding Liraglutide to Oral Antidiabetic Drug Monotherapy: Efficacy and Weight Benefits
Michael Albrecht Nauck, Michel Marre · 2009 · Postgraduate Medicine
The clinical profile and association of delirium in geriatric patients with hip fractures in a tertiary care hospital in India.
Anugrah Chrispal, Kuruvilla Prasad Mathews, V Surekha · 2010 · PubMed
Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation?
Michael Albrecht Nauck, O. Baranov, Robert A. Ritzel, Juris Jendrik Meier · 2013 · Diabetologia
Clinical Effectiveness of Liraglutide Across Body Mass Index in Patients with Type 2 Diabetes in the United States: A Retrospective Cohort Study
A.S. Chitnis, Michael Lee Ganz, Nicole N. Benjamin, J Langer, Mette Hammer · 2014 · Advances in Therapy
Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction
Quan Qi, Lei Lu, Haiqing Li, Zhize Yuan, Gaoxian Chen, Miao Lin, Zhengwen Ruan, Xiaofeng Ye, Zeyu Xiao, Qiang Zhao · 2017 · International Journal of Nanomedicine
Effect of liraglutide administration and a calorie-restricted diet on lipoprotein profile in overweight/obese persons with prediabetes
Danit Ariel, Sun H. Kim, Fahim Abbasi, Cindy A. Lamendola, Anni Liu, Gerald M. Reaven · 2014 · Nutrition Metabolism and Cardiovascular Diseases
Hypoglycemic and Hypolipidemic Effects of Leucine, Zinc, and Chromium, Alone and in Combination, in Rats with Type 2 Diabetes
H. Sadri, Negar Nowroozi Larki, Saeed Kolahian · 2017 · Biological Trace Element Research
The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen
Kapitza, Christoph, Zdravkovic, Milan, Hindsberger, Charlotte, Flint, Anne · 2011 · Advances in Therapy
GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?
Arredouani, Abdelilah · 2025 · Pharmacology & Therapeutics
Comparative effectiveness of liraglutide in the treatment of type 2 diabetes
Gian Paolo Fadini, Mauro Rigato · 2014 · Diabetes Metabolic Syndrome and Obesity
Pharmacological management of type 2 diabetes: the potential of incretin‐based therapies
Bernard H. Charbonnel, Bertrand Cariou · 2010 · Diabetes Obesity and Metabolism